Drug Excipient Business Development Reports now Available on Amazon
Drug Patent Watch
FEBRUARY 15, 2024
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch.
Business Development Related Topics 
Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development
Fierce Pharma
MAY 6, 2024
In the role, he'll oversee the drugmaker's portfolio management and business development activities. .” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Key Business Development Skills Every Manager Should Have
BioSpace
JUNE 14, 2021
People working on business development are the ones responsible for dealing with the business side of the organization. Dealing with a lot of people, clients and a huge team is part of this job.
Teva CEO Francis poaches business development head Angus Grant from BeiGene
Fierce Pharma
JULY 28, 2023
Teva’s CEO Richard Francis is adding to his constellation of new executives with a fresh business development hire from BeiGene. as its EVP of business development, the Israeli-American generics giant announced Friday. Teva has enlisted BeiGene's Angus Grant, Ph.D,
Immunovant data show potential for autoimmune disease drug
Bio Pharma Dive
SEPTEMBER 26, 2023
Much anticipated clinical trial data for Immunovant’s experimental FcRn inhibitor could catalyze business development decisions for its parent, Roivant Sciences.
Clinical Trials 
278
278 
Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference
Fierce Pharma
NOVEMBER 10, 2022
Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference. Thu, 11/10/2022 - 13:14.
Teva Appoints Angus Grant, PhD, as EVP of Business Development
Pharmaceutical Commerce
JULY 28, 2023
The pharma and biotech exec will begin his role on Aug.
Hasten Biopharmaceutic raises $315m for pipeline assets development
Pharmaceutical Technology
APRIL 20, 2023
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors.
Development 246
246 
BioMarin taps Amgen, Roche vets in executive reshuffle
Bio Pharma Dive
AUGUST 21, 2024
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
Viatris sells off consumer, women’s health drugs in asset sales
Bio Pharma Dive
OCTOBER 2, 2023
The divestments will bring in more than $3 billion as the company works to reduce its debt and plan for future business development.
Sales 173
173 
BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales
Pharmaceutical Technology
FEBRUARY 2, 2024
Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
Sales 130
130 
eClinical Provider Crucial Data Solutions Appoints Brian Dufresne as SVP Business Development
Crucial Data Soutions
JUNE 27, 2022
Reno, NV, June 27, 2022 — Crucial Data Solutions (CDS), a provider of innovative low-code/no-code technologies to advance clinical research, announced today that industry veteran Brian Dufrense has joined the company as Senior Vice President, Business Development.
After Idorsia deal, Viatris' dealmaking appetite remains strong, CEO says
Fierce Pharma
FEBRUARY 28, 2024
On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business development grabs—especially on the comme | On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business (..)
Pfizer records 6% decline in revenue in Q3 2022
Pharmaceutical Technology
NOVEMBER 2, 2022
In addition, we continue to make progress toward our goal of adding at least $25 billion in risk-adjusted 2030 revenues to Pfizer’s portfolio through business development.”.
Pfizer reports 30% operational growth in full-year 2022 revenues
Pharmaceutical Technology
FEBRUARY 1, 2023
“We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond.”
Juice Pharma Introduces New EVP of Business Development
Pharmaceutical Commerce
JULY 20, 2023
Experienced exec joins the agency with over three decades of driving brand growth.
TANAKA Contributes to Ambix Life Science Fund
Pharma Mirror
SEPTEMBER 6, 2021
Through this equity contribution, TANAKA will reinforce its overseas business development in addition to its domestic business development and contribute to the development of a safe and secure healthcare industry. -based venture capital management company (“Ambix Ventures”).
Life Science 130
130 
PTC and Blackstone enter financing partnership of up to $1bn
Pharmaceutical Technology
OCTOBER 28, 2022
PTC will use the network and life sciences capabilities of Blackstone to expand its business development works. PTC Therapeutics chief financial officer Emily Hill said: “This strategic financing will support the acceleration of PTC’s robust and diversified pipeline, business development opportunities and general corporate purposes.
Life Science 130
130 
The commercialisation of quantum science in pharma
pharmaphorum
MAY 21, 2024
In today’s podcast, web editor Nicole Raleigh speaks with PASQAL’S technical business developer Europe, Krisztian Benyo, PhD, about the pharma applications and commercialisation of quantum science.
After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals
Fierce Pharma
JUNE 11, 2024
Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami.
Making connections and getting noticed as a biotech start-up
pharmaphorum
FEBRUARY 1, 2024
On today's podcast, brought to you by Kadans Science Partners, host Jonah Comstock is joined by Bradley Hardiman, Astellas Pharma’s Senior Director of Business Development; Mike Murray, head of Murray International Partners Ltd; and Mairi Dillon, Kadans' Ecosystem Manager for UK & Ireland.
How Much Business Development Should Clinical Research Sites Be Doing
Clinical Trial Gurus
MARCH 19, 2021
Every site should have a strategy for finding new studies regardless of the current number of actively enrolling studies. Established sites tend to have a larger network that can help them find new studies based on the site’s reputation.
Well-Versed Sharkey Ready to Take GeoVax from Buyer to Seller
BioSpace
JULY 11, 2022
Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.
CAR-TCR 2023 – Tim McGuire
pharmaphorum
OCTOBER 20, 2023
At CAR-TCR last month in Boston, pharmaphorum Editor in Chief Jonah Comstock grabbed some time with Tim McGuire, director of business development at biomanufacturer Resilience.
Business Development Is For Everyone In Clinical Research! Pharmacist Turned Entrepreneur Explains!
Clinical Trial Gurus
OCTOBER 5, 2021
Oftentimes as clinical research professionals we do not think of ourselves as sales people but expanding your opportunities in the life sciences industry is as important as anything else we will ever do for our careers.
CRA Academy Graduate Becomes Business Development Manager For A Clinical Research Vendor
Clinical Trial Gurus
MARCH 26, 2021
Clinical research is a large industry with a multitude of career options to choose from. Most people who enter the industry might only be familiar with CRC or CRA roles but the reality is that there are other supporting roles that are equally as essential for supporting the industry.
Bristol Myers CEO outlines transition strategy featuring 11 key brands, more dealmaking
Fierce Pharma
FEBRUARY 2, 2024
The strategy includes 11 key growth brands and a continued emphasis on business development.
Branding 122
122 
The 2024 biopharma M&A landscape: An overview
pharmaphorum
FEBRUARY 29, 2024
On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.
Business Development For Clinical Research Sites and Job Seekers in a Post COVID19 World
Clinical Trial Gurus
JUNE 13, 2021
In addition, job seekers are also scrambling to find strategies for further developing their career pathways. COVID-19 has changed the way clinical research sites look for studies. In this webinar, Chris and myself share some pragmatic approaches for all to implement in order to take advantage of a HOT clinical trials industry!
InterVenn, T-knife and Zentara Bolster Missions with New Funding
BioSpace
AUGUST 1, 2021
The three companies will use their proceeds to support the development of their pipelines through additional business development opportunities.
Blueprint Medicines announces financing partnerships for $1.25bn
Pharmaceutical Technology
JULY 1, 2022
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. The company noted that the deal will bring substantial non-dilutive, low-cost capital to boost innovation and growth.
Medicine 147
147 
Viatris makes good on CEO's dealmaking promise with $25M licensing pact for Lexicon's heart med Inpefa
Fierce Pharma
OCTOBER 17, 2024
and Europe.
Licensing 97
97 
Selkirk Pharma: Adapting to regulatory shifts and market demand
BioPharma Reporter
APRIL 22, 2024
Ahead of CPHI North America, we caught up with Lisa Stiles, director, business development at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.
Marketing 87
87 
Russia: Pfizer stops clinical trials, Bayer halts investment projects
BioPharma Reporter
MARCH 14, 2022
Pfizer Inc says it will maintain its supply of medicines to Russia but it will not initiate new clinical trials in the country, while Bayer is suspending investment projects and new-business development in that market.
China Puts Renewed Focus on Monoclonal Antibodies in COVID-19 Fight
BioSpace
DECEMBER 8, 2021
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, as also working on monoclonal antibody treatments.
Antibody 82
82 
Four Biopharma Companies Raise Hundreds of Millions in Series B Rounds
BioSpace
APRIL 12, 2021
This morning, multiple companies announced hundreds of millions of dollars were raised in Series B rounds that will be used to advance therapeutics and business development programs.
SCOPE - the go-to destination for sharing innovative approaches in clinical operation
Outsourcing Pharma
JANUARY 24, 2024
Dawn Kaminski is vice president, of business development (BD) operations at eClinical Solutions and is responsible for working with the BD team as a subject matter expert for services and technology, strategically positioning the organization to acquire new business and expand the business offerings within current customers.
How Are Biopharma Companies Evaluating Partnerships in the Rare Disease Space?
Camargo
SEPTEMBER 23, 2020
Thomas Kassberg, Chief Business Officer, Ultragenyx.
Aqilion and Merck partner to develop TAK1 protein inhibitors
Pharmaceutical Technology
FEBRUARY 16, 2023
Aqilion CEO Sarah Fredriksson said: “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making. “We
Protein 147
147 
Revolutionizing Orthopedic Joint Replacement — Interview with Ben Sexson, Co-Founder, CEO, Monogram Orthopedics – Xtalks Life Science Podcast Ep. 142
XTalks
JANUARY 17, 2024
Monogram is focused on developing patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. Ben is an engineer by training and before joining Monogram, he served as the Director of Business Development at Pro-Dex, an OEM manufacturer of Orthopedic Robotic End-Effectors.
Life Science 115
115 
Hasten buys commercial rights for Roche’s Rocephin in China
Pharmaceutical Technology
MAY 5, 2023
This investment helped the firm to support the business development of its pipeline assets. In April 2023, Hasten secured an investment of $315m as part of a funding round jointly led by the Singapore-based CBC Group and Abu Dhabi’s sovereign wealth fund, Mubadala Investment.
Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Pharmaceutical Technology
APRIL 3, 2023
In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
Development 130
130 
STAT+: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
STAT News
JANUARY 13, 2023
De Backer, the head of strategy and business development at Bayer, has so many meetings on her schedule that there’s no telling where one ends and another begins. Marianne De Backer’s iPhone calendar is a solid block of green.
Neumora raises funds for precision neuro therapies development
Pharmaceutical Technology
OCTOBER 12, 2022
This considerable amount of progress in such a short period of time reflects our urgency to address the relative lack of progress and innovation in neuroscience with our data-driven, precision medicine approach.”.
Development 147
147 
Let's personalize your content